Navigation Links
Existing Radiation Countermeasures Inadequate! Development of Rx100 Promises Change!
Date:3/19/2011

JOHNSON CITY, Tenn., March 19, 2011 /PRNewswire/ -- Recent events in Japan have caused the world to focus on unintended radiation exposure. Exposure to radiation can be a cause for concern – especially if radiation levels reach or exceed 1 Gy. Radiation targets rapidly proliferating cells of the body. Cells of the hematopoietic system (bone marrow) and the gastrointestinal (GI) tract are two such cell types. Damage to these cells initiates programmed cell death (apoptosis).

First responders, healthcare professionals, and citizens lack sufficient medications to prevent cellular damage and death due to exposure to significant levels of whole-body irradiation. Agents that protect from radiation exposure are divided into three categories: 1) Agents that must be administered before cellular exposure to ionizing radiation or "radioprotectants;" 2) Agents that can be administered after exposure and which will forestall the cascade of events leading to radiation-induced damage or "radiomitigants;" and 3) Agents that can facilitate or promote endogenous recovery from radiation-induced damage or "regenerators."

To date, the FDA has approved a few radioprotectants. These include:

  • Prophylactic potassium iodide to protect the thyroid from exposure to excess I 132.
  • Laxatives and chelating agents (i.e. diethylene triamine pentaacetic acid ("DTPA"), etc., to decrease exposure by binding and promoting urinary excretion.
  • Absorbing agents such as Prussian Blue to limit GI absorption or high oral doses of calcium to compete with intestinal absorption of milk contaminated with strontium 90.

There are a small handful of agents presently under development as radiomitigants. These include Rx100. Although under development, this product shows significant promise because of its ability to be administered up to 72 hrs.(1) after exposure to high levels of radiation ̵
'/>"/>

SOURCE RxBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax
2. Yongye International Expands Its Existing Production Capacity by 50% and Provides Updates on Customer List Acquisition
3. Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement
4. ChemImage Works to Improve Existing Methods of Imaging Untreated Fingerprints on Paper Substrates
5. Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles
6. Australian Patent Issued to CreAgri® for Ultraviolet Radiation (UVR) Protection by its Hydroxytyrosol-Based Formulations
7. Bolder BioTechnology Receives $1.2 Million from NIH to Study Long-Acting G-CSF and GM-CSF Analogs in Treating Acute Radiation Syndrome
8. Rx100 Rescues Life if Administered Up to 72 Hours After Exposure to Lethal, Whole-Body Radiation!
9. Accuray to Showcase CyberKnife Treatment Planning Capabilities at Preeminent Radiation Oncology Conference
10. Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market
11. New near-field radiation therapy promises relief for overheating laptops
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Sinovac Biotech Ltd. (Nasdaq: SVA), a leading ... unaudited financial results for the fourth quarter and full ... 2014 Financial Highlights(Compared to the fourth quarter 2013) ... of 11.4% from $22.9 million in the prior year ... pandemic influenza vaccine of $0.1 million in the fourth ...
(Date:4/20/2015)... 2015 Whitehouse Laboratories is pleased and ... most recent Food and Drug Administration (FDA) inspection and ... five day, GMP compliance inspection, as based upon 21CFR ... through April 6th and was granted NAI (no action ... the strict Good Manufacturing Practice (GMP) quality system required ...
(Date:4/17/2015)... Reed Technology and Information Services ... management, preparation, and submission to the U.S. Food and ... new Lot Distribution Report (LDR) service for manufacturers of ... with the FDA’s new rule on electronic submission of ... the volume and timing of particular biologics introduced to ...
(Date:4/17/2015)... April 17, 2015  Guggenheim Securities, the investment banking ... the hiring of William Tanner as a ... Mr. Tanner will start work at Guggenheim in May ... office. "Bill brings a wealth of ... our experienced and highly acclaimed healthcare team," said ...
Breaking Biology Technology:Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 3Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2
... , NEW ... a new market research report is available ... Trial Locations - Eastern Europe: Market dynamics ... , http://www.reportlinker.com/p0165658/Emerging-Clinical-Trial-Locations---Eastern-Europe-Market-dynamics-and-the-changing-healthcare-and-regulatory-environment.html , Over ...
... , Former Majority Leader Richard ... Communities for "Best and Brightest Forum on Medical Innovation" ... of New Jersey,s most prominent leaders in biopharmaceuticals, research, medicine ... discuss the importance of medical innovation in New Jersey, and ...
... , SPRINGFIELD, Ill., Dec. 1 Prairie ... it was recently awarded two statuettes at the first-ever CLIO ... The CLIO Healthcare Awards recognizes creative excellence and innovation in ... CLIO Awards, one of the world,s most recognized awards competitions ...
Cached Biology Technology:Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 2New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 3New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 4New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 5Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 2
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... 23, 2015, after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... PHILADELPHIA , Feb. 20, 2013   LaserLock ... in providing state-of-the-art authentication solutions to governments, pharmaceuticals, ... a provisional patent application for a Characteristic ... simultaneously identify counterfeit products and protect against identity ...
... in the Journal of the Academy of Nutrition and ... a connection between diet and acne, particularly from high glycemic ... (MNT) can play an important role in acne treatment. ... their adolescent and young adult years. Acne influences quality of ...
... brain, patterned on engineering control theory, may some day ... and migraines, according to a Penn State researcher who ... more complex brain models emerge. "The dual ... of the most important developments in mathematics of the ...
Cached Biology News:LaserLock Technologies Files for Provisional Patent Enabling Mobile Phones with Anti-Counterfeiting Technology 2Increasing evidence links high glycemic index foods and dairy products to acne 2Engineering control theory helps create dynamic brain models 2Engineering control theory helps create dynamic brain models 3Engineering control theory helps create dynamic brain models 4
... Each vial contains 200 g of ... receptor sequence (C-terminal amino acids 380-402; GLTPSAWEASSLRSSRHSGLSHF. ... an antigen for production of Cayman's EP1 ... can be used in conjunction with this ...
Anti-ZFP200 Family: Zinc Finger Peptide Sequence: CGKSFNHKTNLNKHER...
Complete cell culture media with cytokines...
Consists of 4 separate 100mM solutions (ATP,GTP,CTP and UTP pH 7.5) as sodium salts. 98% Pure by HPLC...
Biology Products: